CLINUVEL’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. CLINUVEL develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.
CLINUVEL aims to be a global leader in pharmaceutical development and maintain its expertise on the interaction of light and skin. We continually strive to further develop and share knowledge on all aspects related to photoprotection, environmental factors and related risks; particularly in relation to pigmentation disorders, light-related skin diseases and skin cancer.
CLINUVEL’s objectives are to serve patients, physicians and shareholders in the process of its product development. To this end, the company collaborates with all leading regulatory authorities to best serve and protect those dedicated to the company’s success.